that you tube video discusses this specific combination of biomarkers predictive of mortality. useful but he says himself "you still need a treatment"
he disclosed funding from biogen and incycye and talks about the research trials of their respective drugs for gvhd, natalizumab monoclonal antibody and incyte jak inhibitor itacitinib and rux
natalizumab has since failed dismally despite the robust trial design leveraging this biomarker based risk stratification methodology.. as did itacitinib in its phase 3.
any other promising treatments?
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-264
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.010(1.05%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 94.5¢ | 96.5¢ | 94.0¢ | $730.6K | 767.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 65656 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 4072 | 5 |
View Market Depth
| Last trade - 12.32pm 21/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |